ClinicalTrials.gg
RecruitingNCT06644625Updated Jul 13, 2026

CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study

An observational study in Multiple Myeloma, Multiple Myeloma Progression and Monoclonal Gammopathy of Undetermined Significance (MGUS), sponsored by Wake Forest University Health Sciences. Recruiting at 1 site in United States. Open to participants aged 30 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Wake Forest University Health Sciences · Observational

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,665
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 24 studies in Multiple Myeloma by Wake Forest University Health Sciences — 5 open to participants now, 7 under way, none of them phase 3. Multiple Myeloma · Wake Forest University Health Sciences.

Started
2025
with 1 other
Observational
7 of 24
4 open now
Registered
22nd of 24
by date

Among the 24 studies in Multiple Myeloma by Wake Forest University Health Sciences, this one is one of 2 that started in 2025, is one of 7 observational ones, and was the 22nd registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

5 of the 24 studies in Multiple Myeloma by Wake Forest University Health Sciences are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 30 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Multiple Myeloma by Wake Forest University Health Sciences, or all of them as a file.
02

Study summary

The purpose of this study is to identify multiple myeloma in the precancerous MGUS stage in order to reduce the risk of delayed diagnosis of multiple myeloma, decrease morbidity related to multiple myeloma at progression, and improve long term outcomes.

Read the detailed description

The CHAAMP Internal Pilot is a pilot and feasibility study conducted to evaluate the feasibility of the trial methods before a full-scale screening effort is launched. High risk individuals 30 years of age or older residing in Charlotte or surrounding area will be screened for MGUS over one-year period with a target enrollment of 1665 participants. Individuals screening positive for monoclonal gammopathy will be provided a clinic referral for further diagnostic evaluation to confirm MGUS, SMM, or other PCD-related disorder, and will be given the opportunity to consent for the Longitudinal portion of the study. Participants diagnosed with MGUS and smoldering multiple myeloma will be prospectively followed for 10 years per protocol. Participants diagnosed with other plasma cell disorders will have their diagnosis and baseline data captured in the registry and followed for overall survival only.

03

Conditions studied

  • Multiple Myeloma
  • Multiple Myeloma Progression
  • Monoclonal Gammopathy of Undetermined Significance (MGUS)
  • Smoldering Multiple Myeloma (SMM)
  • Plasma Cell Disorders

Keywords

  • multiple myeloma
  • hematology
  • plasma cell disorders
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

High risk individuals with age greater than or equal to 30 years at the time of consent, residing in the Charlotte, NC or surrounding areas.

Eligibility criteria

SCREENING Inclusion Criteria:

  • Age 30 years or older at the time of consent
  • Either:

    1. Self-identify as Black and/or African American OR
    2. First-degree relatives (parents, siblings, or children) of patients of any race or ethnicity diagnosed with a plasma cell disorder, including MGUS, smoldering multiple myeloma (SMM), multiple myeloma (MM), solitary plasmacytoma, plasma cell leukemia, AL amyloidosis, POEMS syndrome, and Waldenström's Macroglobulinemia
  • Capable and willing to provide . NOTE: HIPAA (Health Insurance Portability and Accountability Act) authorization for the release of personal health information may be included in the informed consent or obtained separately
  • Reside in Charlotte, NC, or the surrounding area, based on self-report

SCREENING Exclusion Criteria:

  • Self-reported history of MGUS, SMM, MM, AL amyloidosis, plasma cell leukemia, solitary plasmacytoma, Waldenstrom Macroglobulinemia, and POEMS.

LONGITUDINAL Inclusion Criteria:

  • Test positive for monoclonal gammopathy during screening portion of the study
  • Consent to the longitudinal portion of the study

LONGITUDINAL Exclusion Criteria:

  • The participant previously underwent diagnostic work up as part of CHAAMP Internal Pilot that did not result in a diagnosis of MGUS, Smoldering Multiple Myeloma or other non-plasma cell disorder.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,665 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • MGUS and Smoldering Multiple Myeloma

    Participants diagnosed with MGUS and smoldering multiple myeloma

    Other: Blood draw for the laboratory assessment

  • Other Plasma Cell Disorders

    Participants diagnosed with other plasma cell disorders

    Other: Blood draw for the laboratory assessment

Interventions

  • OtherBlood draw for the laboratory assessment

    Screening blood sample collection to test for MGUS

06

What researchers measure

Primary outcomes

  1. Number of Participants who were Enrolled

    Determined for each potential participant approached to participate in this study (pre-screened), indicating whether or not the participant was enrolled (underwent blood draw to test for monoclonal gammopathy).

    Time frame: Baseline, for an accrual period of one year

Secondary outcomes

  1. Monoclonal Gammopathy at Screening

    A categorical variable will be determined for each enrolled participant indicating whether or not the participant had monoclonal gammopathy identified on screening blood draw, or if the test results were indeterminate (options: monoclonal gammopathy, no monoclonal gammopathy, unknown/indeterminant test results).

    Time frame: From enrollment to availability of lab results, approximately 30 days

  2. PCD Diagnosis at Screening

    PCD diagnosis at screening will be determined as a nominal categorical variable indicating the participant's PCD diagnosis at screening. The categorical variable will include the following factor levels: monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), multiple myeloma (MM), AL amyloidosis, other PCD/ lymphoproliferative disorder, monoclonal gammopathy with unknown diagnosis, or no monoclonal gammopathy. Reason for unknown diagnosis may be due to non-definitive results, no results due to lab error, sampling issues, or participant did not get complete diagnostic work up.

    Time frame: From enrollment to completion of diagnostic work up, approximately 90 days

  3. PCD Diagnosis During Follow-Up

    PCD diagnosis during follow-up will be determined as a categorical variable for each new PCD diagnosis indicating whether the participant had the type of PCD diagnosed over the course of the follow up period on the study. The types of new PCD diagnosis will include SMM, MM, AL amyloidosis, and other PCD diagnosis, per diagnostic criteria as defined in Appendix A. Date of each new PCD diagnosis will also be captured.

    Time frame: From enrollment to completion of follow up (10 years)

  4. CRAB Criteria at MM Diagnosis

    CRAB criteria at MM diagnosis are defined as a binary variable indicating whether the participant had CRAB criteria at the time of MM diagnosis. CRAB criteria include hypercalcemia, renal insufficiency, anemia, or bone lesions as defined per IMWG. This will be evaluated only in the subjects diagnosed with MM during longitudinal follow-up

    Time frame: From enrollment to completion of follow up (10 years)

  5. Time to MM Diagnosis

    Time to MM diagnosis is defined as the duration of time from MGUS diagnosis (or SMM diagnosis for participants diagnosed with SMM at screening) to diagnosis of MM per IMWG criteria. The date of MM diagnosis is the date of the first assessment that identified MM. If the participant died without a diagnosis of MM, time to MM diagnosis will be calculated at the date of death, with death as a competing risk event. For surviving subjects who do not have documented MM diagnosis, time to MM diagnosis will be censored at the date of the last documented disease evaluation that confirmed no MM diagnosis.

    Time frame: From enrollment to completion of follow up (10 years)

  6. Number of Participants who Interacted with a Community Champion

    Interaction with a community champion will be captured for each potential participant as a binary variable indicating whether or not the potential participant interacted with a study-associated community champion prior to enrollment or prior to declining participation. This will be captured via the "Interaction with Community Champion Survey".

    Time frame: Baseline

  7. Impact of Interaction with a Community Champion

    Community champion impact will be reported by each enrolled participant that interacted with a community champion. It will be captured as an ordered categorical variable (5-point Likert scale) indicating the level of impact that the community champion had on the participant's decision to participate in the study. This will be captured via the "Interaction with Community Champion Survey".

    Time frame: Baseline

  8. Number of MGUS Participants who Participate in Longitudinal Portion of Study

    For each participant that is determined to have MGUS at screening, a binary variable will be captured, indicating whether or not the participant consented to be followed longitudinally in the longitudinal portion of the study.

    Time frame: From enrollment to presentation of second (longitudinal) consent, approximately 90 days

  9. Barriers to Screening Participation

    For participants who are approached but do not verbally agree to participation in the study, verbal reason for declining study participation will be reported and captured via a "Barriers to Participation Survey" that includes multi-select discrete options as well as an "Other" reason with free text option.

    Time frame: Baseline

  10. Barriers to Longitudinal Participation

    For participants with monoclonal gammopathy identified during screening but who do not agree to participate in the longitudinal portion of the study, reason for declining longitudinal participation will be reported and captured via a "Barriers to Participation Survey" that includes multi-select discrete options as well as an "Other" with free text option.

    Time frame: From enrollment to presentation of second (longitudinal) consent, approximately 90 days

  11. Psychological Counseling Referral

    For each participant with monoclonal gammopathy identified during screening, a binary variable indicating whether a psychological counseling referral was accepted after learning of positive results.

    Time frame: From enrollment to completion of diagnostic work up, approximately 90 days.

  12. Light Chain MGUS Diagnosis at Screening

    Determined as a binary variable indicating whether the participant had light chain MGUS diagnosis at screening. Three definitions of light chain MGUS (with applicable reference ranges for FLC ratio, involved FLC) will be utilized to evaluate this endpoint: standard IMWG diagnostic criteria \[with FLC ranges from Katzmann et al (2002)\], iStop MM criteria incorporating age and renal function \[Long et al (2025)\], and Dana Farber Cancer Institute criteria incorporating race \[Bertamini et al (2025)\].

    Time frame: From enrollment to completion of diagnostic work up, approximately 90 days.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Jan 2035, 118 months after the start.

Of 173 non-industry observational studies under Multiple Myeloma, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 31. This study's planned 118 months is above that.

Counting every sponsor, half of 239 studies reached it within 57 months; a quarter within 30 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2024
First posted
Oct 16, 2024
StartActual
Mar 1, 2025
Primary completionEst.
Jan 2035
CompletionEst.
Jan 2035
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06644625
Collaborators
Atrium Health Levine Cancer Institute
Responsible party
Sponsor
First posted
Oct 16, 2024
Start date
Mar 1, 2025
Primary completion
Jan 2035 (estimated)
Completion
Jan 2035 (estimated)
Last update
Jul 13, 2026

Study contacts

Margarita Dzhanumova
Contact
margarita.dzhanumova@atriumhealth.org
704-754-3768
Manisha Bhutani, MD
principal investigator · Atrium Health Wake Forest Baptist Comprehensive Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion